Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTJTSX4)

• DTT Name: Glypican-3 (GPC3) DTT Info
• Gene Name: GPC3

Molecule-Related Drug & Molecule List

18 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Codrituzumab	DMDWG36	Hepatic metastasis	2D80	Phase 2	[1]
GC33	DMXTD74	Hepatocellular carcinoma	2C12.02	Phase 2	[2]
GPC-3298306	DMOHAS2	Hepatocellular carcinoma	2C12.02	Phase 2	[3]
RG7686	DM6CNFW	Hepatocellular carcinoma	2C12.02	Phase 2	[2]
SAR444200	DM7J5H0	Aggressive cancer	2A00-2F9Z	Phase 2	[4]
CAR-T cells targeting Glypican-3 (GPC3)	DMDSKR2	Hepatocellular carcinoma	2C12.02	Phase 1/2	[5]
CAR-T cells targeting GPC3	DM6H1MQ	Hepatocellular carcinoma	2C12.02	Phase 1/2	[6]
GPC3-CART cells	DMGN679	Hepatocellular carcinoma	2C12.02	Phase 1/2	[7]
Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs	DMDO6J1	Hepatocellular carcinoma	2C12.02	Phase 1/2	[8]
TAI-GPC3-CART cells	DMCFSZ5	Hepatocellular carcinoma	2C12.02	Phase 1/2	[9]
Anti-GPC3 CAR T	DMUMWFK	Hepatocellular carcinoma	2C12.02	Phase 1	[10]
CAR-GPC3 T Cells	DMQH2DK	Lung squamous cell carcinoma	2C25.2	Phase 1	[11]
ERY974	DM9YNTO	Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]
GAP T cells	DMIXMQE	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]
GLYCAR T cells	DM1PK0T	Hepatocellular carcinoma	2C12.02	Phase 1	[13]
GPC3 targeting CAR-T cells	DMVWHS1	Hepatocellular carcinoma	2C12.02	Phase 1	[14]
TAK-102	DMD79TX	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]
CAR-GPC3 T cell	DMBDT3V	Hepatocellular carcinoma	2C12.02	Clinical trial	[16]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2013 Feb 15;19(4):920-8.
• [3] Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma. Nihon Rinsho Meneki Gakkai Kaishi. 2008 Oct;31(5):383-91.
• [4] Clinical pipeline report, company report or official report of Sanofi
• [5] ClinicalTrials.gov (NCT02723942) CAR-T Cell Immunotherapy for HCC Targeting GPC3
• [6] ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
• [7] ClinicalTrials.gov (NCT03130712) A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART)
• [8] ClinicalTrials.gov (NCT03084380) Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)
• [9] ClinicalTrials.gov (NCT02715362) A Study of GPC3 Redirected Autologous T Cells for Advanced HCC
• [10] ClinicalTrials.gov (NCT02395250) Anti-GPC3 CAR T for Treating Patients With Advanced HCC
• [11] ClinicalTrials.gov (NCT03146234) CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma
• [12] ClinicalTrials.gov (NCT02932956) Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)
• [13] ClinicalTrials.gov (NCT02905188) Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)
• [14] ClinicalTrials.gov (NCT03198546) GPC3-T2-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
• [15] ClinicalTrials.gov (NCT04405778) A Study of TAK-102 in Adult With Previously-Treated Solid Tumors. U.S. National Institutes of Health.
• [16] ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors